Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 6, 2011, Pages 428-431

  Córdova, Ezequiel ^a   Loiza, Eliana ^a   Porteiro, Norma ^a   Mingrone, Horacio ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

Argentina; Etravirine; HIV resistance; NNRTI

Indexed keywords

ETRAVIRINE; LAMIVUDINE; NEVIRAPINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARGENTINA; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; RESISTANCE ASSOCIATED MUTATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ARGENTINA; DRUG RESISTANCE, VIRAL; FEMALE; FORECASTING; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; PYRIDAZINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 79959335987     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2011.03.003     Document Type: Conference Paper

References (9)

1. Johnson LB, Saravolatz LD. Etravirine, a next-generation non-nucleoside reverse-transcriptase inhibitor. Clin Infect Dis. 2009;48:1123-8.
2. Vingerhoets J, Buelens A, Peeters M, Picchio G, Pambuyzer L, Van Barck H, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. Presentado en: 11th European AIDS Conference, Madrid, Spain, 24-27 October 2007.
3. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Presentado en: XVIIth International Drug Resistance Workshop, Sitges, Spain, 10-14 June 2008.
4. Hadad M, Stawiski E, Benhamida J, Coakley E. Improved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype. 17th Conference on Retroviruses and Opportunistic Infection 2010. Paper 574.
5. Johnson VA, Brun-Vézinet F, Clotet B, Günthard H, Kuritzkes D, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1. Top HIV Med. 2009;17:138-45.
6. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with Non-nucleoside reverse transcriptase inhibitor resistance? AIDS. 2008;22:989-90.
7. MacArthur RD, Hupller Hullsiek K, Peng G, van den Berg-Wolf B, Crane LR, Novak RM, et al. Failing therapy with efavirenz results in significantly fewer mutations limiting to etravirine than failing therapy with nevirapine: on treatment analyses from the CPCRA FIRST Study. Antivir Ther. 2008;13 Suppl 3:A141.
8. Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W, et al. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort Infected with non-B subtype HIV-1. Curr HIV Res. 2010;8:194-8.
9. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, et al. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1 infected patients. Antimicrob Agents Chemother. 2010;54:72-7.